RE-SPECT CVT: a Randomised, Open-label, Exploratory Trial With Blinded Endpoint Adjudication (PROBE), Comparing Efficacy and Safety of Oral Dabigatran Etexilate Versus Oral Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis Over a 24-week Period
Phase of Trial: Phase III
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Dabigatran etexilate (Primary) ; Warfarin
- Indications Venous thrombosis
- Focus Therapeutic Use
- Acronyms RE-SPECT CVT
- Sponsors Boehringer Ingelheim
- 30 May 2017 Planned End Date changed from 20 Apr 2018 to 19 May 2018.
- 30 May 2017 Planned primary completion date changed from 6 Apr 2018 to 5 May 2018.
- 19 Jan 2017 Status changed from not yet recruiting to recruiting.